Home>>Signaling Pathways>> Others>>Methyocarbamol

Methyocarbamol (Synonyms: AHR 85, Guaiacol Glyceryl Ether Carbamate, Guaiphenesin Carbamate, NSC 170960)

Catalog No.GC16339

Methyocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel.

Products are for research use only. Not for human use. We do not sell to patients.

Methyocarbamol Chemical Structure

Cas No.: 532-03-6

Size Price Stock Qty
10mM (in 1mL DMSO)
$57.00
In stock
50mg
$47.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms.Target: Carbonic AnhydraseMethocarbamol is the carbamate of guaifenesin, but does not produce guaifenesin as a metabolite, because the carbamate bond is not hydrolyzed metabolically; metabolism is by Phase I ring hydroxylation and O-demethylation, followed by Phase II conjugation. All the major metabolites are unhydrolyzed carbamates. Methocarbamol is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm [1, 2].

References:
[1]. Bruce, R.B., L.B. Turnbull, and J.H. Newman, Metabolism of methocarbamol in the rat, dog, and human. J Pharm Sci, 1971. 60(1): p. 104-6.
[2]. Sica, D.A., et al., Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol, 1990. 39(2): p. 193-4.

Reviews

Review for Methyocarbamol

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Methyocarbamol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.